
R406 free base
CAS No. 841290-80-0
R406 free base( —— )
Catalog No. M16126 CAS No. 841290-80-0
R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 58 | In Stock |
![]() ![]() |
10MG | 88 | In Stock |
![]() ![]() |
25MG | 177 | In Stock |
![]() ![]() |
50MG | 320 | In Stock |
![]() ![]() |
100MG | 507 | In Stock |
![]() ![]() |
500MG | 1062 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameR406 free base
-
NoteResearch use only, not for human use.
-
Brief DescriptionR406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay.
-
DescriptionR406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.
-
In VitroR406 inhibits adenosine A3 receptor (IC50=0.081 μM), adenosine transporter (IC50=1.84 μM), and monoamine transporter (IC50=2.74 μM).R406 inhibits Huh7 hepatocyte, A549 epithelial, and H1299 lung cancer lines with EC50s of 15.1, 2.9 and 6.3 μM, respectively.R406 inhibits phosphorylation of Syk substrate LAT in mast cells and BLNK/SLP65 in B cells. Western Blot Analysis Cell Line:Cultured human mast cells (CHMC Concentration:0.016, 0.08, 0.4, 2 μM Incubation Time:40 minutes Result:Inhibited all other kinases tested at 5 to 100 fold less potency than Syk as judged by phosphorylation of target proteins.
-
In VivoR406 (5 and 10 mg/kg) shows efficacy in the amelioration of the Arthus reaction and in reducing clinical symptoms in the collagen antibody-induced arthritis (CAIA) and K/BxN models of rheumatoid arthritis (RA). Immune complex (IC)-mediated inflammation is reduced by inhibition of Fc receptor signaling with R406. Animal Model:Female Balb/c mice (6-8 weeks) with CAIA Dosage:5 and 10 mg/kg Administration:Administered orally, b.i.d, for 14 days, starting 4 hours after antibody challenge on day 0. Result:Reduced inflammation and swelling, and the arthritis progressed more slowly in treated animals than in vehicle controls.Animal Model:Female C57BL/6 mice with arthritis Dosage:10 mg/kg Administration:Administered orally one hour before serum injection; b.i.d; for 13 days Result:Delayed the onset and reduced the severity of clinical arthritis. Paw thickening and clinical arthritis were reduced by approximately 50%.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorSyk
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number841290-80-0
-
Formula Weight470.45
-
Molecular FormulaC22H23FN6O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 21 mg/mL (44.63 mM)
-
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4)C=C3)=N2)=CC(OC)=C1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
molnova catalog



related products
-
LM22B-10
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.
-
R788 free base
Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM.
-
Syk-IN-3
Syk-IN-3 is a Syk inhibitor with potential anti-inflammatory and anticancer activity and can be used to study immune dysregulation.